British Thoracic Society Recommendations on Nebulised Therapy for Asthma

1. Position on N‑acetylcysteine (NAC) Nebulisation

• The British Thoracic Society (BTS) guidelines (1993 & 1997) do not recommend NAC nebulisation for the treatment of asthma; mucolytics are omitted from the list of recommended nebulised agents for both acute and chronic asthma management. [1][2]3

2. Acute Severe Asthma – Preferred Nebulised Regimen

• Nebulised short‑acting β₂‑agonists (e.g., salbutamol 5 mg or terbutaline 10 mg) delivered with oxygen are the first‑line therapy for acute severe asthma. 1
• Systemic corticosteroids should be administered immediately (prednisolone 30–60 mg orally or hydrocortisone 200 mg IV). 1
• When life‑threatening features are present (peak expiratory flow < 33 % predicted, silent chest, cyanosis), add nebulised ipratropium bromide 0.5 mg to the β₂‑agonist regimen. 1

Strength of evidence: BTS guideline recommendation (expert consensus based on clinical trials).

3. Chronic Persistent Asthma – Criteria for Nebulised Therapy

• Nebulised bronchodilators are reserved for Step 4 or higher in patients with daily wheeze despite optimized inhaler therapy. [2][4]5
• Prior to initiating chronic nebuliser use, clinicians must demonstrate ≥ 15 % improvement in mean baseline peak flow over at least five consecutive days of monitoring. [2][5]6
• Typical chronic dosing: salbutamol 2.5 mg or terbutaline 5 mg, with optional ipratropium 250–500 µg as needed. [2][4]5

Strength of evidence: BTS guideline recommendation (derived from longitudinal outcome studies).

4. Avoidance of NAC in Routine Asthma Care

• Do not prescribe NAC for routine asthma exacerbations when excessive secretions are not the primary problem; NAC offers no bronchodilator effect and may precipitate bronchospasm. [1][2]
• The BTS guidelines emphasize that most asthma patients do not require mucolytic therapy, and percussive physiotherapy is deemed unnecessary in acute attacks. 1

Strength of evidence: BTS guideline recommendation (clinical consensus).

5. Safety Considerations for Nebulised Fluids

Strength of evidence: BTS guideline recommendation (based on safety observations).

Management of Post‑Nebulization Hiccups in Asthma

Assessment of Nebulized Dose and Severity Criteria

• Verify the nebulized β‑agonist dose: chronic asthma typically uses salbutamol 2.5 mg or terbutaline 5 mg; acute severe asthma may require salbutamol 5 mg or terbutaline 10 mg. 8
• Assess acute‑severe‑asthma features that justify maintaining high‑dose nebulization despite hiccups: respiratory rate ≥ 25 /min, heart rate ≥ 110 /min, and peak expiratory flow ≤ 50 % predicted. 8

Criteria for Continuing Nebulized Therapy

• Continue nebulized therapy only if the patient demonstrates ≥ 15 % improvement in mean baseline peak flow over at least five days of monitoring. 8

Dose Optimization and Transition to Inhaler Therapy

• If hiccups recur with repeated nebulizations, consider reducing the β‑agonist dose or switching to a hand‑held inhaler when clinically appropriate. [9][8]
• Before ongoing nebulized treatment for chronic asthma, ensure the patient has trialed optimized hand‑held inhaler therapy (salbutamol 200–400 µg four times daily or equivalent). 9

Algorithmic Decision Steps

• First nebulization hiccups: observe, reassure, and complete treatment if acute‑severe‑asthma criteria are met. 8
• Hiccups resolve within minutes‑hours: maintain the standard nebulized regimen as indicated. 8
• Recurrent hiccups with subsequent treatments: reduce β‑agonist dose or transition to a hand‑held inhaler when disease severity permits. 9